The Department of Pharmaceuticals (DoP) in India is preparing to engage with the Ministry of Petroleum and Natural Gas (MoPNG) and the Department of Fertilisers to secure necessary ammonia supplies for the pharmaceutical industry. The country is currently facing a significant ammonia shortage due to disruptions linked to the West Asia conflict, which has raised alarms among drug manufacturers. India, being one of the largest ammonia importers, relies heavily on imports from Oman, Saudi Arabia, and Qatar. The pharmaceutical sector typically needs 12,000 tonnes of ammonia each month but can only source 5,000-6,000 tonnes at present. Recent regulatory changes have mandated that surplus ammonia from urea manufacturing must be sold for fertiliser production, limiting availability for pharmaceutical use. This order follows a notification from the MoPNG that restricts natural gas usage in fertiliser plants to production purposes only, further complicating the supply situation. Industry experts warn that this shortage could have a cascading effect on the supply chain, particularly impacting micro, small, and medium enterprises (MSMEs) that depend on ammonia sourced from urea plants.